Purdue, Teva and J&J Sued Over Opioid Overdoses

Purdue, Teva and J&J Sued Over Opioid Overdoses 1   A new government study found that more than one third of U.S. adults were prescribed opioid medications in 2015. Though many chronic pain sufferers legitimately require these meds to manage pain, the increased number of people taking opioids increases risks associated with them. These addictive […]

FacebookTwitter

New FDA Commissioner’s Goals

New FDA Commissioner’s Goals 1 The new FDA commissioner Dr. Scott Gottlieb, who was confirmed in May, has made his main goal clear: streamlining FDA operations to get new generic drugs and medical devices available more quickly. An analysis by the FDA suggests that the introduction of two generic versions of a drug cuts the […]

FacebookTwitter

Three MD to NP Comparisons

A new study shows Nurse Practitioner (NP) visits correlate to a big drop in hospital admissions. Hospitalization rates plummeted 61%, and ER visits fell 64% among a group of patients who received home visits from NPs during a six-month period in 2016, according to a University of Rhode Island College of Nursing study. Previous studies show similar results proving that NPs can reduce hospitalizations and close a problematic gap between the hospital and primary care that MDs cannot address alone. Continue reading…

FacebookTwitter

Future of Off-Label Promotion

Between Dr. Gottlieb being sworn in as the new FDA commissioner and several recent court cases going in favor of the drugmakers, one has to question if we’ll see a loosening of off-label promotion rules. It’s estimated that one in five prescriptions written in the U.S. are for off-label therapies, and studies have shown much higher percentages of off-label use in certain specialties. Continue reading…

FacebookTwitter

Pharma Rep Access in Decline

Less than 44% of physicians are accessible to pharma reps this year compared to 51% in 2014 and 65% in 2012. Nearly a decade of data has shown a steady decline in physician access according to ZS – a global consulting and research company. That’s a big pharma marketing problem. Continue reading…

FacebookTwitter
1 2 3 4 10